Tumor necrosis factor and Alzheimer's disease: A cause and consequence relationship

Klinik Psikofarmakoloji Bulteni

Volumn 22, Issue 1, 2012, Pages 86-97

  Sharma, Vivek ^a   Thakur, Vinay ^a   Bhandari, Suresh ^a   Singh, Shesh Nath ^a   Guleria, Rajender ^a  

^a Govt College of Pharmacy   (India)

Author keywords

Alzheimer's disease; Amyloid ; Apoptosis; iNOS; MAPK; NGF; TNF

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALZHEIMER DISEASE; APOPTOSIS; BEHAVIOR; BRAIN; BRAIN DEVELOPMENT; BRAIN FUNCTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLINERGIC SYSTEM; CHROMOSOME 12P; CHROMOSOME 1P; CIRCADIAN RHYTHM; CYTOKINE PRODUCTION; DISEASE COURSE; GENETIC ASSOCIATION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; NERVE CELL PLASTICITY; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; SLEEP; STRESS; UPREGULATION;

EID: 84863299227     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5455/bcp.20120112064639     Document Type: Review

References (127)

1. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6(2):107-16.
2. Aggarwal Bharat B, Sethi Gautam, Baladandayuthapani Veera, Krishnan Sunil, Shishodia Shishir. Targeting Cell Signaling Pathways for Drug Discovery: An Old Lock Needs a New Key. Journal of Cellular Biochemistry 2007;102(3):580-92.
3. Arezoo Campbell. Inflammation, Neurodegenerative Diseases, and Environmental ExposuresAnn. N Y Acad Sci 2004;1035(12):117-32.
4. Maccioni RB, Leonel E, Rojo Jorge A, Fernández Rodrigo O. Kuljis. The Role of Neuroimmunomodulation in Alzheimer's Disease. Annals of the New York Academy of Sciences 2009;1153(2):240-6.
5. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. I: Disorders of thought content. Br J Psychiatry 1990;157 (7):72-6, 92-4
6. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44(1):181-93.
7. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12(9):1005-15.
8. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116(7):1793-801.
9. Rutter M, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110(4):380-5.
10. Schmidt M, Duncan BB. Diabesity: An inflammatory metabolic condition. Clin Chem Lab Med 2003;41(9):1120-30.
11. Miller GE, Freedland KE, Duntley S, Carney RM. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am J Cardiol 2005;95(3):317-21.
12. Peila R, Launer LJ. Inflammation and dementia: epidemiologic evidence. Acta Neurol Scand Suppl. 2006;185:102-6.
13. Fudenberg HH, Singh VK. Alzheimer's Syndrome.Prognosis of subsets with different etiology and preliminary effects of immunotherapy. Drug Dev Res 1991;15(2):165-9.
14. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer disease. Can J Neurol Sci 1989;16(4 Suppl):S516-S27.
15. Singh VK, Fudenberg HH, Brown FR. Immunologicdysfunction: Simultaneous study of Alzheimer's diseaseand older Down's patients. Mech Ageing Dev 1987;37(3):257-64
16. Alexander EL, Lijewski JE, Jerdan MS, Alexander GE. Evidence for an immunopathogenetic basis for central nervous system disease in Alzheimer's disease. Arthritis Theum 1988;29:1223-7.
17. Qunanian A, Guilbert B, Renversez JC, Seigneurin JM, Avameas S. Antibodies to viral antigens, xenoantigensand autoantigens in Alzheimer's disease. J Clin Lab Anal 1990;4(10):367-75.
18. Jerzy Leszek, Irena Dobrzanska, Kazirnierz Gasiorowski. Alzheimer's disease immunological aspects. Acta Neurobil Exp 1993;53(1):351-5.
19. Boulanger LM, Huh GS, Shatz CJ. Neuronal plasticity and cellular immunity: shared molecular mechanisms. Curr Opin Neurobiol 2001;11(5):568-78.
20. Lau FC, Shukitt-hale B, Joseph JA. Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress. SubcellBiochem 2007;42:299-318.
21. David JP, Ghozali F, Fallet-Bianco C, Wattez A, Delaine S, Boniface B, et al. Glial reaction in the hippocampal formation is highly concentrated with aging in human brain. Neurosci Lett 1997;235(1-2):53-6.
22. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol 1999;57(6):563-581.
23. Rivest S. Molecular insights on the cerebral innate immune system, Brain Behav. Immun 2003;17(1):13-9.
24. Nadeau S, Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J Neurosci 2003;23(13):5536-44.
25. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer'sdisease cortices. FEBS Lett 1996;285(1):111-4
26. Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett 1991;129(2):318-20.
27. Hofman FM, Hinton DR, Johnson K, and Merrill JE. Tumor necrosis factor in multiple sclerosis brain. J Exp Med 1998;170:607-12
28. Merrill JE. Proinflammatory and anti-inflammatorycytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome. J Immunother 1992;12(3):167-170
29. Beeson PB. Temperature-elevating effect of a substance obtained from poly morpho nuclear leucocytes. J Clin Invest 1948; 27:524.
30. Lawrence Leung and Catherine M Cahill. TNF-α and neuropathic pain - a review. J Neuroinflammation. 2010;7:27.
31. Sauder DN. The role of epidermal cytokines in inflammatory skin diseases. J Invest Dermatol 1990;95(5):27S-28S.
32. Compston A, Zajicek J, Sussman J, Webb A, Hall G, Muir D, Shaw C, Wood A, Scolding N. Glial lineages and myelination in the central nervous system. J Anat 1997;190 (Pt 2):161-200.
33. Lisak RP, Skundric D, Bealmear B, Ragheb S. The role of cytokines in Schwann cell damage, protection, and repair. J Infect Dis. 1997;176 Suppl 2:S173-9.
34. Sharma Rashmi, Sharma Lal Chaman, Mahajan Anil. Biological agents targeting beyond TNF-alpha. Indian J Crit Care Med 2008;12(4):181-9.
35. Bickels J, Kollender Y, Merinsky O, Meller I. Coley's toxin: historical perspective. Isr Med Assoc J 2002;4:471-2.
36. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975 Sep;72(9):3666-70.
37. Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddel DV. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985;82(18):6060-4.
38. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334(26):1717-25
39. Idriss HT, Naismith JH. TNFα and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000;50(3):184-95.
40. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104(4):487-501.
41. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27(1):19-26.
42. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and newdrugs. Drug Discov Today 2009;14(23-24):1082-8.
43. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nature Rev Immunol 2009;9(4):271-85.
44. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nature Reviews Drug Discovery 2010;9(6):482-93.
45. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385(6618):729-33.
46. Wang J, Al-Lamki RS, Zhang H, Kirkiles-Smith N, Gaeta ML, Thiru S, et al. Histamine antagonizes tumor necrosis factor(TNF) signalling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003;278(24):21751-60.
47. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008;214(2):149-60
48. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999;11(6):783-93.
49. Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 2001;22(6):873-83.
50. Saha RN, Liu X, Pahan K. Up-regulation of BDNF in astrocytes by TNFalpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 2006;1(3):212-22.
51. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994;6(4):341-60.
52. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 1999;10(2):119-30.
53. Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 1997;778(2):265-71.
54. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J et al. TNF is a potent anti-inflammatory cytokine in autoimmunemediated demyelination. Nat Med 1998;4(1):78-83.
55. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNFa promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001;4(11):1116-22.
56. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3(9):745-56.
57. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56(4):321-39.
58. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease; J Neuroinflammation 2008;17:5:45.
59. Li R, Yang L, Lindholm K, Konishi Y, Yue X, Hampel H, Zhang D, Shen Y. Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. J Neurosci 2004;24(7):1760-71.
60. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997;17(8):2653-7.
61. Luth HJ, Munch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 2002;953(1-2):135-43.
62. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43(2): 109-42.
63. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, et al. Connecting TNF-a Signaling Pathways to iNOS Expression in a Mouse Model of Alzheimer's Disease: Relevancefor the Behavioral and Synaptic Deficits Induced byAmyloid β Protein. J Neurosci 2007;27(20):5394-404.
64. Vallance P, Leiper J. Blocking NO synthesis: how, where and why?. Nat Rev Drug Discov 2002;1(12):939-50.
65. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidativedamage in Alzheimer's disease brain: central role for amyloid betapeptide. Trends Mol Med 2001;7(12):548-54
66. Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of-amyloid and IFN-y. Brain Res 1995;692(1-2):207-14
67. Meda L, Cassatella MA, Szendrei GI, OtvosJr L, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by p-amyloid protein and interferon-a. Nature 1995;374(6523):647-50.
68. Eberhardt W, Kunz D, Hummel R, Pfeilschifter J. Molecular cloning of the rat inducible nitric oxide synthase gene promoter. Biochem Biophys Res Commun 1996;223(3):752-6.
69. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87(4):1620-4.
70. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000;279(6):L1005-L1028.
71. Smith AD, Castro SL, Zigmond MJ. Stress-induced Parkinson's disease: a working hypothesis. Physiol Behav 2002;77(4-5):527-31.
72. Esch T, Stefano GB, Fricchione GL, Benson H. The role of stress in neurodegenerative diseases and mental disorders. Neuro Endocrinol Lett 2002;23(3):199-208.
73. Munhoz CD, García-Bueno B, Madrigal JL, Lepsch LB, Scavone C, Leza JC. Stress-induced neuroinflammation: mechanisms and new pharmacological targets. Brazilian Journal of Medical and Biological Research 2008;41(12):1037-46.
74. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J Neurochem 1993;60(5):1650-7.
75. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79(4):1431-1568.
76. Beart PM, O'Shea RD. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol 2007;150(1):5-17.
77. Leza JC, Salas E, Sawicki G, Russell JC, Radomski MW. The effects of stress on homeostasis in JCR-LA-cp rats: the role of nitric oxide. J Pharmacol Exp Ther 1998;286(3):1397-1403.
78. Madrigal JL, Garcia-Bueno B, Caso JR, Perez-Nievas BG, Leza JC. Stress-induced oxidative changes in brain. CNS Neurol Disord Drug Targets 2006;5(5):561-8.
79. Varfolomeev E E, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004;116(4):491-7.
80. Burek MJ, Oppenheim RW. Programmed cell death in the developing nervous system. Brain Pathol 1996;6(4):427-446.
81. Narayanan A. Cell death in the developing nervous system. In: Hannun Y and Boustany R, editors. Apoptosis in Neurobiology. CRS Press. 1999: 13-24.
82. Roth KA. Caspases, apoptosis, and Alzheimer disease: causation, correlation, and confusion. J Neuropathol Exp Neurol 2001;60(9):829-38.
83. Richter C. Pro-oxidants and mitochondrial calcium: thier relationship to apoptosis and oncogenesis. Febs Lett 1993;325(1-2):104-7.
84. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18(1):44-51.
85. Oppenheim RW. Cell death during development of the nervous system. Annu Rev Neurosci 1991;14:453-501.
86. Su JH, Anderson AJ, Cummings B, Cotman CW. Immunocytochemical evidence for apoptosis in Alzheimer's disease. Neuro Report 1994;5(18):2529-33.
87. Kruman I, Bruce-Keller AJ, Bredesen DE, Waeg G, Mattson MP. Evidence that 4-hydroxynonenal mediates oxidative stressinduced neuronal apoptosis. J Neurosci 1997;17(13):5089-100.
88. Deshmukh M, Johnson EM. Programmed cell death in neurons: focus on the pathway of nerve growth factor deprivation induced death of sympathetic neurons. Mol Pharmacol 1997;51(6):897-906.
89. Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A, et al. Mitochondrial MnSOD prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation and mitochondrial dysfunction. J Neurosci 1998;18(2):687-97.
90. Pang Z, Geddes JW. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. J Neurosci 1997;17(9):3064-73.
91. Tenneti L, D'Emilia DM, Troy CM, Lipton SA. Role of caspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J Neurochem 1998;71(3):946-59.
92. Mattson MP, Partin J, Begley JG. Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 1998;807(1-2):167-176.
93. Nath R, Probert A, McGinnis KM, Wang KK. Evidence for activation of caspase-3-like protease in excitotoxins and hypoxia/ hypoglycemia-injured cerebrocortical neurons. J Neurochem 1998;71(1):186-95.
94. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG et al. Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis 2001;8(1):162-72.
95. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. Faseb J 2009;23(3):739-50.
96. Cribbs DH, Poon WW, Rissman RA, Blurton-Jones M. Caspase-mediated degeneration in Alzheimer's disease. Am J Pathol 2004;165(2):353-5.
97. Wallach D. Cell death induction by TNF: a matter of self control. Trends Biochem Sci 1997;22(4):107-9.
98. Glazner GW, Chan SL, Lu C, Mattson MP. Caspase-mediated degradation of AMPA receptor subunits: a mechanism for preventing excitotoxic necrosis and ensuring apoptosis. J Neurosci 2000;20(10):3641-9.
99. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23(9):1261-76.
100. Alvarez S, Blanco A, Fresno M, Muñoz-Fernández MÁ. TNF-α contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT. PLoS One 2011;6(1):1-13.
101. Choi DW. Glutamate neurotoxicity and diseases of thenervous system. Neuron 1988;1(8):623-34.
102. Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF-α on glutamatergic synaptic transmissionin the central nervous system. Exp Physiol 2005;90(5):663-70.
103. Golan H, Levav T, Mendelsohn A, Huleihel M. Involvement of tumor necrosis factor alpha in hippocampal development and function. Cerebral Cortex 2004;14(1):97-105.
104. Yang L, Lindholm K, Konishi Y, Li R, Shen Y. Target depletion of distinct tumor necrosis factor receptor subtype reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002;22(8):3025-3032.
105. Cooke SF, Bliss TV. "Plasticity in the human central nervous system". Brain 2006;129(Pt 7): 1659-73.
106. Bliss TV, Collingridge GL. "A synaptic model of memory: long-term potentiation in the hippocampus". Nature 1993;361(6407):31-9.
107. Mayford M, Wang J, Kandel ER, O'Dell TJ. CaMKII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP. Cell 1995;81(6):891-904.
108. Silva AJ, Smith AM, Giese KP. Gene targeting and the biology of learning and memory. Annu Rev Genet 1997;31:527-46.
109. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron 2004;44(1):5-21.
110. Malenka RC, Nicoll RA. Long-term potentiation-a decade of progress? Science 1999;285(5435):1870-4.
111. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M et al. Control of synaptic strength by glial TNFalpha. Science 2002;295(5563):2282-5.
112. Tancredi V, D'Arcangelo G, Grassi F, Tarroni P, Palmieri G, Santoni A et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett 1992;146(2):176-8.
113. Cunningham AJ, Murray CA, O'Neill LA, Lynch MA, O'Connor JJ. Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett 1996;203(1):17-20.
114. Cumiskey D, Butler MP, Moynagh PN, O'Connor JJ. The inhibitory effect of tumour necrosis factor-α on long-term potentiation is attenuated by type 1 metabotropic glutamate receptor blockade. J Physiol 2004;560:23.
115. Benzing T, Kottgen M, Johnson M, Schermer B, Zentgraf H, Walz G, Kim E. Interaction of 14-3-3 protein with regulator of G protein signaling 7 is dynamically regulated by tumor necrosis factor-alpha. J BiolChem 2002;277(36):32954-62.
116. Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005;25(12):3219-28.
117. Vivek Kumar Sharma, Ashok Goyal and Subrahmanya G Sarma. Minocycline decreases acetylcholinestrase activity in intra-cerebroventricular streptozotocin infused rats ijpsr 2010;1:52-7.
118. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT and Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215(4537):1237-9.
119. Coyle JT, Price D, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219(4589):1184-90.
120. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10(2):122-6.
121. Barde YA. The nerve growth factor family. Prog Growth Fact Res 1990;2(4):237-48.
122. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237(4819):1154-62.
123. Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci 1992;15(9):323-31.
124. Thoenen H, Bandtlow C, Heumann R. The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Rev PhysiolBiochemPharmacol 1987;109:146-71.
125. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;207(4558):408-14
126. Fisher W, Sirevaag A, Viegand SJ, Lindsay RM, Bjorlund. A reversal of spatial memory impairments in aged rats by NGF and neurotrophins 2 and 3:4 but not by brain!derivedneurotrophic factor. Proc Natl Acad Sci U S A. 1994;91(18):8607-11.
127. Aloe L, Fiore M, Probert L, Turrini P, Tirassa P. Overexpression of tumour necrosis Factor a in the brain of transgenic Mice differentially alters nerve Growth factor levels and choline Acetyltransferase activity. Cytokine 1999;11(1):45-54.